PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) Chemical Structure

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 43 Publications

12 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

    LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

    Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.

  • The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

    Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

  • Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

    The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

     

     

    2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Features First MEK inhibitor to begin clinical development.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
17 nM 17 nM
In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9 NIDPWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMEKyO|Yh|ryP NGj1bYJUSU6JRWK=
CHP-212 M{LyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DrS2lEPTB;MD6wNlg5PSEQvF2= NGPoSZVUSU6JRWK=
EoL-1-cell NWn3T|JCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLsTWM2OD1yLkC0NVUzKM7:TR?= NH;qRWRUSU6JRWK=
DU-4475 NV3VeHVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPVbIQ6UUN3ME2wMlA4PTl7IN88US=> NFK3NllUSU6JRWK=
MMAC-SF NEPyclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\ITWlEPTB;MD6xNFk4PCEQvF2= NH;h[FlUSU6JRWK=
AGS NFHYR5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMUG3NVMh|ryP NYjid5F7W0GQR1XS
M14 MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMUW0Olgh|ryP MXvTRW5ITVJ?
CP50-MEL-B MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7yV3NKSzVyPUCuNVczPTRizszN Ml76V2FPT0WU
C32 NHvlWGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMUmwO|Ih|ryP NUPoeHFIW0GQR1XS
KMOE-2 MmXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHUTWM2OD1yLkG5O|k2KM7:TR?= MoXOV2FPT0WU
A101D NH\VUpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwMkG0JO69VQ>? NFX3do9USU6JRWK=
KM12 Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfjVllKSzVyPUCuNlQxPTdizszN MX\TRW5ITVJ?
HSC-4 NFPXdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDocHBKSzVyPUCuNlQ{QTVizszN NUnu[VVxW0GQR1XS
NOMO-1 MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvpN|RKSzVyPUCuNlU4PDJizszN MYjTRW5ITVJ?
MZ7-mel MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnJOppKSzVyPUCuNlY{PCEQvF2= MW\TRW5ITVJ?
ACN MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jUd2lEPTB;MD6yOlc{PyEQvF2= NYntbYJsW0GQR1XS
MEL-HO NYXEWVc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DMNGlEPTB;MD6yO|Y2OiEQvF2= NEm5S3BUSU6JRWK=
BHT-101 NWLNcVNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMki2NFYh|ryP NHrKeZdUSU6JRWK=
SK-MEL-28 NXrxN25TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHhUppKSzVyPUCuN|A1ODlizszN MVvTRW5ITVJ?
KG-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHGye4tKSzVyPUCuN|A3PjhizszN MmH4V2FPT0WU
COLO-679 M1fa[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfvbHZIUUN3ME2wMlMzPzJizszN NXHKd5M6W0GQR1XS
SK-MEL-24 NIDPS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwM{K4NVMh|ryP NV\XcohyW0GQR1XS
G-361 Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33xV2lEPTB;MD6zOlc6PSEQvF2= NXeyRXR{W0GQR1XS
KY821 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXpTWM2OD1yLkO3PVEh|ryP MVXTRW5ITVJ?
KASUMI-1 Mn7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljlTWM2OD1yLkO5PUDPxE1? MkLQV2FPT0WU
HL-60 M2j2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLZWIxKSzVyPUCuOFEyODdizszN NYjxdo9jW0GQR1XS
K5 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvZWWo2UUN3ME2wMlQ{OTF5IN88US=> MnnTV2FPT0WU
KU812 M2nHRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHXc|dKSzVyPUCuOFUzQTlizszN MVvTRW5ITVJ?
SH-4 MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXaTWM2OD1yLkS2NlU3KM7:TR?= NHXWU3VUSU6JRWK=
HTC-C3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn4TopDUUN3ME2wMlQ3PTNzIN88US=> MV3TRW5ITVJ?
CP66-MEL M3T5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULMW2toUUN3ME2wMlQ5QDB7IN88US=> M2XKNXNCVkeHUh?=
WM-115 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y0Z2lEPTB;MD60PVI2PyEQvF2= NGXobYJUSU6JRWK=
A2780 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;MeXdKSzVyPUCuOFk5OjNizszN MnfvV2FPT0WU
P12-ICHIKAWA M{D0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwNkGyNlEh|ryP NYPLXWxkW0GQR1XS
HMV-II NFWzdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\HW3l1UUN3ME2wMlY1PDZ3IN88US=> NEnRe4pUSU6JRWK=
HT-144 NWKweW5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHewWINKSzVyPUCuOlQ3PTdizszN NH7ENpVUSU6JRWK=
LB2518-MEL M3zoeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfBc5pKSzVyPUCuO|E3OzJizszN NUfQVlBlW0GQR1XS
NCI-SNU-1 MmrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkK3TWM2OD1yLke1OFM{KM7:TR?= MWPTRW5ITVJ?
C2BBe1 NYLQ[XR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULmXWJRUUN3ME2wMlgyODJ|IN88US=> MmKwV2FPT0WU
PSN1 NX;aXlQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TWTmlEPTB;MD65OlE6PiEQvF2= Mnm3V2FPT0WU
UACC-257 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfyT|VKSzVyPUCuPVY1PzNizszN M4LpUnNCVkeHUh?=
RVH-421 M2\Z[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnUUJZKSzVyPUCuPVcyQCEQvF2= MXTTRW5ITVJ?
GP5d NUTpR3h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvFTWM2OD1yLkm4N|A5KM7:TR?= M4PGV3NCVkeHUh?=
TYK-nu NHX0NmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFwMEOxO|Ih|ryP Ml2xV2FPT0WU
SK-N-AS M4e0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq0UllNUUN3ME2xMlA4QTR5IN88US=> M1OyZXNCVkeHUh?=
SW620 NVXFTXA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP3dJlKSzVyPUGuNVM2OzRizszN MVLTRW5ITVJ?
HuP-T4 M{[5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwMUizOVkh|ryP M4\MWnNCVkeHUh?=
A549 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofITWM2OD1zLkG5OVc3KM7:TR?= Ml;WV2FPT0WU
Mewo MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLTTWM2OD1zLkKwNlc3KM7:TR?= MnnKV2FPT0WU
ONS-76 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFwMkKwOFkh|ryP MX;TRW5ITVJ?
SK-MEL-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;hTWM2OD1zLkKzOFE6KM7:TR?= MlLSV2FPT0WU
RCM-1 NIP4PIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTBTWM2OD1zLkK0NFQ4KM7:TR?= MmDDV2FPT0WU
H-EMC-SS NFnySoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfUTWM2OD1zLkK5OlA5KM7:TR?= Mo\XV2FPT0WU
NCI-H2291 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwM{K1N|Yh|ryP NIX2cmVUSU6JRWK=
SW1463 NFXlT5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LSdWlEPTB;MT6zN|czOSEQvF2= NFu4cXNUSU6JRWK=
LS-411N MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHEVoliUUN3ME2xMlQxPTF5IN88US=> Mm[wV2FPT0WU
BV-173 NGXTbYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{WxdWlEPTB;MT60OFAyPSEQvF2= NG\OSIRUSU6JRWK=
LS-513 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLEe4hMUUN3ME2xMlQ2OTl{IN88US=> NUi4V4NuW0GQR1XS
LoVo NWntNodFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\LU|lKSzVyPUGuOFY{QTlizszN NXvVVY86W0GQR1XS
HO-1-N-1 NIfFOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv2NnRKSzVyPUGuOVE3OzRizszN MmfxV2FPT0WU
ML-2 NFrLb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknnTWM2OD1zLkWyPFY5KM7:TR?= MWLTRW5ITVJ?
NCI-H1437 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwNUWyO|Uh|ryP MWLTRW5ITVJ?
SW1116 NWDQbXQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;GTWM2OD1zLkW2N|k5KM7:TR?= NWHoT|FMW0GQR1XS
A4-Fuk MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[3d3JKSzVyPUGuOVcxPDVizszN MVnTRW5ITVJ?
HD-MY-Z MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\FbHJKSzVyPUGuOVc{PzZizszN MoO5V2FPT0WU
SK-MEL-2 M{\CWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTTTWM2OD1zLkW3OFU6KM7:TR?= NHLHSnFUSU6JRWK=
RT-112 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jkWmlEPTB;MT61PFk2OiEQvF2= MY\TRW5ITVJ?
COLO-829 NHLwVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn1WWpoUUN3ME2xMlYzOjN{IN88US=> M{f5XHNCVkeHUh?=
OVCAR-5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDDfHJXUUN3ME2xMlc4Pjh5IN88US=> NXTBR|hIW0GQR1XS
NB69 M1PlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTFwN{i0Olkh|ryP NV31UIJJW0GQR1XS
NCI-H292 NUSzc2NQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4L0V2lEPTB;MT64OlY6QSEQvF2= NHPwZWJUSU6JRWK=
LOXIMVI MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\vTWM2OD1zLki5OFI4KM7:TR?= MkXmV2FPT0WU
BPH-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H6cGlEPTB;MT64PVU6OSEQvF2= MkT3V2FPT0WU
A375 NF\oTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEm4WVNKSzVyPUGuPFk4OTRizszN MVfTRW5ITVJ?
LCLC-97TM1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy1VYlKSzVyPUGuPVIzPTZizszN Mn7sV2FPT0WU
RXF393 NYraWIpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3XVYE2UUN3ME2xMlk4QDh5IN88US=> NVWxdo9MW0GQR1XS
HCC70 NGr2d5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jiOWlEPTB;Mj6wNlQzPiEQvF2= NVTOXGVXW0GQR1XS
EM-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknMTWM2OD1{LkC3NVk5KM7:TR?= M2LMfHNCVkeHUh?=
MZ2-MEL M2PHfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PsS2lEPTB;Mj6xNVEzPyEQvF2= NH2wXWdUSU6JRWK=
HN MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP4TmZKSzVyPUKuNVYzPzhizszN NFjadGhUSU6JRWK=
A2058 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJwMUmyO|kh|ryP MWDTRW5ITVJ?
NB7 NH\zfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3R[5JKSzVyPUKuN|QxQDZizszN NEjyW3pUSU6JRWK=
DOK NXv6O2xFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJwM{W3O|Mh|ryP NXPWNnE3W0GQR1XS
CAL-27 NWjRcWRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJwM{myN|Yh|ryP NYTZV4FKW0GQR1XS
BB65-RCC MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\KbmlEPTB;Mj60NFY4PCEQvF2= MljWV2FPT0WU
RD NX\xbYFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;kVo1kUUN3ME2yMlQ1PzJ|IN88US=> NWS2b2dlW0GQR1XS
KNS-62 NFW3Z2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jJUWlEPTB;Mj61NVE3PCEQvF2= NEnQOW5USU6JRWK=
EW-13 Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJwNU[zN|kh|ryP M1T1NHNCVkeHUh?=
DB MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfY[JhKSzVyPUKuOVg4QDhizszN MVvTRW5ITVJ?
HCC2218 M4HsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;ZN4h2UUN3ME2yMlY1Pzd6IN88US=> MXLTRW5ITVJ?
L-363 NInyc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS0TWM2OD1{Lke0N|ch|ryP MWjTRW5ITVJ?
CHL-1 M1Kydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJwOEC3PFUh|ryP NV:zclUxW0GQR1XS
BFTC-905 M2jp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LLR2lEPTB;Mj64NlU{KM7:TR?= MlrRV2FPT0WU
HCE-T NWmycoh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfBeGhKSzVyPUKuPFMzPjRizszN NHHIOmtUSU6JRWK=
COLO-792 MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTJwOESwNlch|ryP NFXEN4ZUSU6JRWK=
LB2241-RCC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7wUGh1UUN3ME2yMlg2QDl|IN88US=> NHPVN5pUSU6JRWK=
CAL-39 MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnNVHRkUUN3ME2yMlg6QTl7IN88US=> NGfuTWZUSU6JRWK=
T-24 NFH0VlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwOUGxNVIh|ryP MXHTRW5ITVJ?
NCI-H727 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj0TWM2OD1{LkmxO|k3KM7:TR?= M2rvVnNCVkeHUh?=
Ca9-22 M2jFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGe4O3lKSzVyPUKuPVczPTVizszN NF;3flNUSU6JRWK=
MIA-PaCa-2 Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTNwMEC3PFEh|ryP NYDpbpRlW0GQR1XS
HT-1080 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnKOHhyUUN3ME2zMlAyQTl5IN88US=> NHHneWNUSU6JRWK=
D-423MG NIfncZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjiO2dKSzVyPUOuNFc4PTNizszN MmTFV2FPT0WU
LAMA-84 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PhWmlEPTB;Mz6xN|U5KM7:TR?= M2e4eXNCVkeHUh?=
SW780 NWLLN4V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm5XYpKSzVyPUOuNVQzOjlizszN M1jxWnNCVkeHUh?=
KU-19-19 M3HjT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO5WVBwUUN3ME2zMlE4ODN2IN88US=> NHf3XmhUSU6JRWK=
COLO-741 NEL6bYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jnRWlEPTB;Mz6xPFY4OyEQvF2= M3TkNHNCVkeHUh?=
HSC-3 NGHac2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjnTWM2OD1|LkKzNVUyKM7:TR?= NVLQd|BIW0GQR1XS
SN12C NFHHO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTNwMkS3NFEh|ryP M2jlT3NCVkeHUh?=
786-0 M2KxTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjLcIVYUUN3ME2zMlI4OjR|IN88US=> M3v0VHNCVkeHUh?=
GAK NYmwelBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTBXJpUUUN3ME2zMlMzPTZzIN88US=> MX3TRW5ITVJ?
PANC-03-27 M4LIU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnWwTWM2OD1|LkO1NFQ2KM7:TR?= MWTTRW5ITVJ?
CTB-1 NV\yVohUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7jXYk{UUN3ME2zMlQ4ODR5IN88US=> MVnTRW5ITVJ?
A427 M4m1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTNwNUm1OVYh|ryP NHzTSFNUSU6JRWK=
EGI-1 NIq1cmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\0fWREUUN3ME2zMlYxPTh|IN88US=> NEDneWVUSU6JRWK=
U-2-OS NEf4O25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfX[JpZUUN3ME2zMlY4OjV4IN88US=> MVHTRW5ITVJ?
NCI-SNU-5 NWHhN4lDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS5TWM2OD1|Lk[3O|Mh|ryP MnjWV2FPT0WU
SK-LU-1 NX7xd3Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTNwNki3PVgh|ryP Mnn1V2FPT0WU
697 NFX6WYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;MTWM2OD1|Lk[5OlA{KM7:TR?= NIq1eYtUSU6JRWK=
HPAF-II Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTNwN{W0PUDPxE1? MVjTRW5ITVJ?
NCI-H2087 NEn3[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjKdYpvUUN3ME2zMlg1Pjd{IN88US=> NYDDc3dLW0GQR1XS
SK-MEL-3 NHzrUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvjTWM2OD1|Lki1NVU1KM7:TR?= MnTWV2FPT0WU
CGTH-W-1 NF7vcWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS4dmpKSzVyPUOuPFU4OjVizszN MWnTRW5ITVJ?
8505C MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljnTWM2OD1|LkmwNFc5KM7:TR?= M3\hO3NCVkeHUh?=
GAMG Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqwTWM2OD12LkCyN|c4KM7:TR?= M4rwW3NCVkeHUh?=
SW626 NU\pboVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3YcpZpUUN3ME20MlA1PDhizszN MYjTRW5ITVJ?
CAL-62 NV;QOW51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXqUmRKSzVyPUSuNFc1OyEQvF2= M2rXWHNCVkeHUh?=
MHH-PREB-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjVelVbUUN3ME20MlEzOTFzIN88US=> Mm\MV2FPT0WU
RPMI-7951 M3zNZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PmXGlEPTB;ND6yOVU5QSEQvF2= MYrTRW5ITVJ?
HOP-92 NUGwd3d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPSTWM2OD12LkK1Olch|ryP NXXxcpA2W0GQR1XS
MDA-MB-231 MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTRwMkmyNlMh|ryP NUi0dZRJW0GQR1XS
LAN-6 MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HvVWlEPTB;ND6zNVY{PyEQvF2= NF6yXmxUSU6JRWK=
ALL-PO NV70RXVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnLW5FKSzVyPUSuN|YyPTZizszN NYe2Vmo4W0GQR1XS
HH M1vWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HvO2lEPTB;ND60NVU6PyEQvF2= NYXCUnl1W0GQR1XS
IGROV-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFW3OpNKSzVyPUSuOFUyPzFizszN NYjl[HlsW0GQR1XS
NCI-H358 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLBNpF6UUN3ME20MlQ2Ozh3IN88US=> NWewPJZEW0GQR1XS
NB5 M{TsZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED3eY1KSzVyPUSuOlA{PjlizszN NWWwcI5yW0GQR1XS
NCI-H747 M{\vOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3ENWNKSzVyPUSuOlg5ODdizszN NFLBeXVUSU6JRWK=
NH-12 MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTRwN{G2NlUh|ryP NWftSmNVW0GQR1XS
LB1047-RCC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXWxWVh5UUN3ME20Mlc{QDF3IN88US=> MYPTRW5ITVJ?
EFO-27 NYjlUHhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XGeGlEPTB;ND63PFY3PyEQvF2= MYLTRW5ITVJ?
EPLC-272H NYfVUJJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTRwOUm2Olkh|ryP MWjTRW5ITVJ?
CAL-54 NWfHbHByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7CeVFuUUN3ME21MlAzPjl3IN88US=> M2e5e3NCVkeHUh?=
H4 NXjHOFhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYH3T2psUUN3ME21MlA1OjV3IN88US=> MXLTRW5ITVJ?
MOLT-13 NE\ac3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf1NIUzUUN3ME21MlA3Pzd4IN88US=> M{fxPHNCVkeHUh?=
CAL-33 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\yUmlEPTB;NT6xNlMyPyEQvF2= M4L5[3NCVkeHUh?=
23132-87 NYfnVGdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFi0W5pKSzVyPUWuNVY5PzJizszN Ml;DV2FPT0WU
UM-UC-3 Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonNTWM2OD13LkG4NFQ4KM7:TR?= NW\GTZlUW0GQR1XS
HuH-7 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\QPWc4UUN3ME21MlI4OTR5IN88US=> MULTRW5ITVJ?
BCPAP NHHpdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rWe2lEPTB;NT6zNlk3QSEQvF2= NYr2[5F4W0GQR1XS
AsPC-1 M4joVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS3ZlBoUUN3ME21MlM3PzZ|IN88US=> M1X6RXNCVkeHUh?=
NCI-H1155 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTHXVBKSzVyPUWuOFAxPTFizszN MnjpV2FPT0WU
GT3TKB NYPIfpNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fPVWlEPTB;NT60OlU6QCEQvF2= NWLDe2R7W0GQR1XS
HCC2998 NYXMU5RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTVwNEmxNFkh|ryP M{LQenNCVkeHUh?=
NUGC-3 M1XscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjBTWM2OD13LkS5N|AzKM7:TR?= MmPlV2FPT0WU
Hs-578-T MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj5S4pxUUN3ME21MlU{Pzl2IN88US=> NIDJTlRUSU6JRWK=
FADU NUX0dXJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDqfVI{UUN3ME21MlU2PzJ4IN88US=> M4e1NXNCVkeHUh?=
NBsusSR NHnkVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vDNGlEPTB;NT61O|E2PSEQvF2= M3H0W3NCVkeHUh?=
ME-180 MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq2S25YUUN3ME21MlU5ODl{IN88US=> MWjTRW5ITVJ?
SW1710 MmTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVyzOZdSUUN3ME21MlYyPjV2IN88US=> M{DZV3NCVkeHUh?=
HuP-T3 M2XjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHxSoJKSzVyPUWuOlIxOjlizszN M4C1NHNCVkeHUh?=
HOS MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoX4TWM2OD13Lk[yPVI{KM7:TR?= Mn;OV2FPT0WU
PA-1 NFzFOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTVwNkSyOlUh|ryP NXq2S2dwW0GQR1XS
LU-99A NEm4dIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTVwNk[0OVEh|ryP M4Pv[XNCVkeHUh?=
RS4-11 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXf5SYZOUUN3ME21MlY3Pzd3IN88US=> M1O2W3NCVkeHUh?=
TE-8 NEf4SWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTVwNki1N|ch|ryP MXvTRW5ITVJ?
RERF-LC-MS MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rTRmlEPTB;NT62PFgxOyEQvF2= NVLFeFZRW0GQR1XS
MEL-JUSO MkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTVwN{O3PEDPxE1? M1fzN3NCVkeHUh?=
SK-MES-1 NYnkb3RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTVwOEO1Nlgh|ryP NVqwNlBuW0GQR1XS
D-263MG MmruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TQd2lEPTB;NT64PFM2OSEQvF2= NEj4RpFUSU6JRWK=
NB10 MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\WUndKSzVyPUWuPFk1PiEQvF2= NYDGc|dSW0GQR1XS
SK-HEP-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PL[GlEPTB;NT65N|Q4OSEQvF2= M3TUd3NCVkeHUh?=
HT-29 MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTVwOUixNVgh|ryP NWHpO4I1W0GQR1XS
KYSE-140 M121cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3j3dWlEPTB;Nj6wNlE5OiEQvF2= NW\CN5NGW0GQR1XS
NCI-H1666 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTZwMEi0OlEh|ryP MofmV2FPT0WU
NCI-H1304 NFvmW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTZwMUm5OEDPxE1? MlzPV2FPT0WU
RPMI-8866 NF3EboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjPZ2tKSzVyPU[uNlE{OTNizszN MnzTV2FPT0WU
MV-4-11 M2LvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\XTWM2OD14LkKzNVk6KM7:TR?= MlTsV2FPT0WU
A431 MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;xTWM2OD14LkK0Nlk3KM7:TR?= NXuwdHFrW0GQR1XS
PANC-10-05 Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHRTWM2OD14LkK4N|Y{KM7:TR?= NXHaTnN3W0GQR1XS
TK10 NFHlR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX3VnRKSzVyPU[uN|I3ODRizszN NGrpfY9USU6JRWK=
NCI-H1975 MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV36c2kzUUN3ME22MlQ4OjF3IN88US=> MU\TRW5ITVJ?
A172 NFP4d4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrXV2E3UUN3ME22MlQ6OTd4IN88US=> MmLwV2FPT0WU
D-566MG M3nieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLVTWlzUUN3ME22MlU1OzB|IN88US=> NEPMOm1USU6JRWK=
NCI-H2122 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTZwNkG1Nlgh|ryP MkThV2FPT0WU
COR-L105 NH;BVHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXnTVg6UUN3ME22MlY2Ojd3IN88US=> MXzTRW5ITVJ?
AN3-CA MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTZwNki2OFEh|ryP NWHyc5JHW0GQR1XS
Calu-6 MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHBNVVKSzVyPU[uO|k3QThizszN M3LYTXNCVkeHUh?=
HCT-116 MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\ocGlEPTB;Nj64NVI3PCEQvF2= MmH4V2FPT0WU
MHH-NB-11 NVPEWFhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonFTWM2OD14Lki1NFAzKM7:TR?= M33FNXNCVkeHUh?=
MFE-280 NEPLZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;5WnR{UUN3ME22Mlg2QTh|IN88US=> MWjTRW5ITVJ?
SW1088 NVHRc4VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXW[WRbUUN3ME22MlkyQTF|IN88US=> NVn6XGJ[W0GQR1XS
SW48 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T6fmlEPTB;Nj65OFUyKM7:TR?= MkjoV2FPT0WU
HuCCT1 NUfXfoxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjTe45KSzVyPUeuNFExOzdizszN Mn;NV2FPT0WU
ACHN MnqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nPSmlEPTB;Nz6wNlk1OyEQvF2= MVjTRW5ITVJ?
8305C NFjBTIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVK5Z4xLUUN3ME23MlA6QTl3IN88US=> MWTTRW5ITVJ?
DoTc2-4510 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTdwMUKxOUDPxE1? NFvRNotUSU6JRWK=
COR-L23 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfiTWM2OD15LkK0OFIh|ryP M3PrVnNCVkeHUh?=
SK-MEL-30 Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TP[mlEPTB;Nz6yOVA5OyEQvF2= MXTTRW5ITVJ?
BE-13 NUPZb4NiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXeyV|IyUUN3ME23MlM{QDN2IN88US=> MYPTRW5ITVJ?
GR-ST NHjOXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfTTWM2OD15LkSwNVc1KM7:TR?= NIrxbHRUSU6JRWK=
LU-135 NHPQcYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\6bnNkUUN3ME23MlU2QTN7IN88US=> Ml:0V2FPT0WU
U-266 MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHjTWM2OD15LkW2Nlg3KM7:TR?= MVPTRW5ITVJ?
NCI-H1355 NWnjS4I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;GUpVKSzVyPUeuOVg3OzVizszN NYnpSZJwW0GQR1XS
NB14 NVHyT4Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mli4TWM2OD15Lk[2OlQzKM7:TR?= M{DlOXNCVkeHUh?=
SCC-25 MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInNV5dKSzVyPUeuO|A6KM7:TR?= NFryNpJUSU6JRWK=
COLO-678 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj2TWM2OD15LkexNFc3KM7:TR?= M1HoWnNCVkeHUh?=
TGBC1TKB M2[2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O3cWlEPTB;Nz64PVM6QCEQvF2= MknLV2FPT0WU
IST-MEL1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVG4RmVMUUN3ME24MlAxPDB4IN88US=> NH[2U5pUSU6JRWK=
ECC10 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnsSmlHUUN3ME24MlA{Ozl3IN88US=> M3TQOnNCVkeHUh?=
EW-16 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRThwMEi0OFUh|ryP NX3pU4FYW0GQR1XS
DOHH-2 NHG1To1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO1[lhmUUN3ME24MlIxODl3IN88US=> MYXTRW5ITVJ?
NCI-H1581 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRThwMk[zNlMh|ryP MVfTRW5ITVJ?
TE-5 NILrNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRThwNEK0Nlkh|ryP M2TLSnNCVkeHUh?=
CAKI-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRThwNUeyNlIh|ryP NUKycopwW0GQR1XS
A673 NWL0PJhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRThwNkOyNFIh|ryP MmLUV2FPT0WU
CAL-12T NWT2XHNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPXXpZ2UUN3ME24MlY2PzV|IN88US=> NWLyZ4FRW0GQR1XS
DBTRG-05MG NVG3S5A2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP2UWpKSzVyPUiuO|Q5PTlizszN MlHhV2FPT0WU
SK-N-FI M2TvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRThwOEGzO|kh|ryP MkHNV2FPT0WU
K-562 MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRThwOEO5OVch|ryP M3f5[3NCVkeHUh?=
SBC-1 M2Plbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoOwTWM2OD16Lki2OlQ2KM7:TR?= NH3RZVhUSU6JRWK=
ES4 MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rRd2lEPTB;OD64Olg5PCEQvF2= MnfEV2FPT0WU
MS-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjFUYRKSzVyPUiuPFc2OTdizszN MojDV2FPT0WU
RKO MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HWUGlEPTB;OD64PVA2PyEQvF2= NUnDbnV4W0GQR1XS
NCI-H1693 NInETYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDK[4lXUUN3ME24MlkzOTdizszN NHnHSZdUSU6JRWK=
SW954 NHPmT3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRThwOU[5O|gh|ryP NH\OXWVUSU6JRWK=
SK-UT-1 NVz4b5lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRThwOUe2PFMh|ryP MV\TRW5ITVJ?
T98G NVizbHpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO3TWM2OD16Lkm5PFQ3KM7:TR?= NXe1e|NyW0GQR1XS
NCI-H2126 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr0NmJKSzVyPUmuNFA5OjZizszN NFX3OGZUSU6JRWK=
TE-12 NIjCVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n2TmlEPTB;OT6wN|M3PyEQvF2= NGPrd4xUSU6JRWK=
DK-MG M{\6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3UTHZ{UUN3ME25MlIyOTlzIN88US=> MUHTRW5ITVJ?
MEG-01 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vpRmlEPTB;OT6yOFk{OSEQvF2= MoPZV2FPT0WU
HCC1937 NEeycXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\wVYhXUUN3ME25MlI6ODlzIN88US=> MoX1V2FPT0WU
MKN45 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjZRo9KSzVyPUmuOFUxPjVizszN MXvTRW5ITVJ?
NCI-H1792 M1fHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL3TWM2OD17LkS1NlE6KM7:TR?= NEDqTnhUSU6JRWK=
SW1417 MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mln6TWM2OD17LkW2PFM4KM7:TR?= MkO3V2FPT0WU
639-V MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDQTWM2OD17Lk[0N|g5KM7:TR?= Ml7KV2FPT0WU
P30-OHK MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPNTplKSzVyPUmuOlU{OTZizszN NGnOS25USU6JRWK=
YKG-1 Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PoZ2lEPTB;OT63OVA{OyEQvF2= M{KyWnNCVkeHUh?=
KGN NFG5bHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{S3bGlEPTB;OT64N|c6PSEQvF2= M{noT3NCVkeHUh?=
MSTO-211H MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjETWM2OD17Lkm1OVI6KM7:TR?= M{W5dnNCVkeHUh?=
NCI-H1573 M{C3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFyLkG1O|Qh|ryP MXLTRW5ITVJ?
NCI-H720 NGHlPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\5TWM2OD1zMD6xPVg6KM7:TR?= MW\TRW5ITVJ?
KARPAS-45 MnnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDzbWF4UUN3ME2xNE4zPzl3IN88US=> M4LlZnNCVkeHUh?=
MDA-MB-175-VII MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTFyLkS4JO69VQ>? NYfDcJR{W0GQR1XS
SK-NEP-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHiTWM2OD1zMD60PVgyKM7:TR?= NIXqeXFUSU6JRWK=
MKN28 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK0TWM2OD1zMD61NVgh|ryP M4DGO3NCVkeHUh?=
KYSE-520 NUTxWFB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFyLkWyJO69VQ>? MVvTRW5ITVJ?
KE-37 MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3xdmlKSzVyPUGwMlUzPzJizszN M17CdnNCVkeHUh?=
VA-ES-BJ NX7YTG5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIH3Wm1KSzVyPUGwMlU3PyEQvF2= MWLTRW5ITVJ?
CCRF-CEM MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjUSmtOUUN3ME2xNE42Pjh2IN88US=> MXfTRW5ITVJ?
GMS-10 NVHuVWd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DWNmlEPTB;MUCuOlA6PCEQvF2= NHL1UHlUSU6JRWK=
NCI-H1623 NHG2c5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfKWYpkUUN3ME2xNE43Ozd7IN88US=> M{LScXNCVkeHUh?=
NEC8 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\0OJBSUUN3ME2xNE44Pzd|IN88US=> MUHTRW5ITVJ?
MOLT-16 NUnvOVNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHvTWM2OD1zMD64NVE{KM7:TR?= MWDTRW5ITVJ?
DJM-1 NGHZWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTFzLkCzO|kh|ryP NXTrPZZTW0GQR1XS
U251 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v2S2lEPTB;MUGuNFQzKM7:TR?= Ml\jV2FPT0WU
SBC-5 MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HUXmlEPTB;MUGuNVQ3PyEQvF2= MWLTRW5ITVJ?
SW756 M{jGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTRO45ZUUN3ME2xNU4zOTV2IN88US=> NHjkS|NUSU6JRWK=
KS-1 NUPyc|RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFzLkK2NVkh|ryP MXnTRW5ITVJ?
SF295 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml70TWM2OD1zMT6zNVA1KM7:TR?= MnzwV2FPT0WU
YH-13 M1flfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTFzLkOyOlch|ryP M4D5[XNCVkeHUh?=
SW837 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzMTWM2OD1zMT6zOVA3KM7:TR?= MnPLV2FPT0WU
KYSE-450 NYTqPYJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;BTWM2OD1zMT60NFU4KM7:TR?= NYriU2FPW0GQR1XS
KYSE-180 NY\rSWtCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXjSYlKSzVyPUGxMlQ5OiEQvF2= MkXoV2FPT0WU
S-117 MoXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\zRWI4UUN3ME2xNU41QDl4IN88US=> NUXyPGsyW0GQR1XS
KOSC-2 MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFzLk[yNlIh|ryP MYfTRW5ITVJ?
KYSE-270 NHrDTZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHQb2NsUUN3ME2xNU45PzR3IN88US=> M330V3NCVkeHUh?=
D-336MG NEjQRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFzLkmwO|Uh|ryP M3PLVHNCVkeHUh?=
KALS-1 NUDIdpBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPyTWM2OD1zMj6wNFE3KM7:TR?= MoXHV2FPT0WU
LB373-MEL-D MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DBe2lEPTB;MUKuNFU{OyEQvF2= NHTMXppUSU6JRWK=
HLE M1THVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DocWlEPTB;MUKuNFU5PSEQvF2= NULkVHN3W0GQR1XS
SJSA-1 M4LFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTF{LkC3N|Uh|ryP MnnwV2FPT0WU
SW1990 MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{POemlEPTB;MUKuNFkyOSEQvF2= NGH3XYxUSU6JRWK=
NOS-1 NYrrTm1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[2dmlEPTB;MUKuNVM2OiEQvF2= MoXmV2FPT0WU
GI-ME-N MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXxTWM2OD1zMj6yNVY{KM7:TR?= NHLJN2dUSU6JRWK=
NCI-H1703 MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17B[WlEPTB;MUKuNlYyPiEQvF2= NHzxTmxUSU6JRWK=
ES7 NFO5PYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPYdHh3UUN3ME2xNk4zPzJ2IN88US=> NGTvVXJUSU6JRWK=
KYSE-510 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonzTWM2OD1zMj61NFc6KM7:TR?= NFLUVFNUSU6JRWK=
BHY M1zkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHNTWM2OD1zMj61N|A4KM7:TR?= Ml\wV2FPT0WU
TCCSUP NVu2VZdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTF{LkW3OVch|ryP MkXPV2FPT0WU
HSC-2 NF74cHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF{LkW5PVYh|ryP M{\V[XNCVkeHUh?=
BEN M4\PZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTVSm45UUN3ME2xNk43OTR|IN88US=> M{XIdnNCVkeHUh?=
769-P MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHpTWM2OD1zMj63PVI1KM7:TR?= NV;Z[GJ[W0GQR1XS
HT Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTF{LkizOFYh|ryP NWPhNHVpW0GQR1XS
LXF-289 NYDIZWFLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzwc|dWUUN3ME2xNk46PTNzIN88US=> NX3ISIh2W0GQR1XS
OVCAR-3 NE[wWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXf0cJBuUUN3ME2xNk46PTZ5IN88US=> MWnTRW5ITVJ?
ATN-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF|LkCxPFQh|ryP NWPJVlVIW0GQR1XS
8-MG-BA NXXKNWdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX:0WZNsUUN3ME2xN{4xPDV3IN88US=> M{nwcHNCVkeHUh?=
SW13 Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T3NGlEPTB;MUOuNVE3PSEQvF2= M2HMeHNCVkeHUh?=
NCI-H1092 M360fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LhS2lEPTB;MUOuNVYzKM7:TR?= M2rsS3NCVkeHUh?=
OAW-42 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDZZWFDUUN3ME2xN{4yQTN5IN88US=> Mo\lV2FPT0WU
NCI-H2452 NGPZbIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEi2fnpKSzVyPUGzMlIyPzVizszN NH[4bI5USU6JRWK=
CAPAN-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rTXmlEPTB;MUOuOVUyPCEQvF2= MlnLV2FPT0WU
NCI-H2009 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVewUVB5UUN3ME2xN{42QTF7IN88US=> MoSzV2FPT0WU
SF268 NXLSPYZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn6TGlyUUN3ME2xN{43OzJ4IN88US=> NXrWUWVxW0GQR1XS
GCIY MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInEeYJKSzVyPUGzMlY6OjdizszN MWXTRW5ITVJ?
OS-RC-2 NITEN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjh[|UyUUN3ME2xN{46PTBzIN88US=> NVLrfVZTW0GQR1XS
GCT MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHhTWM2OD1zMz65Olk4KM7:TR?= MX7TRW5ITVJ?
NB17 M2DFPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\yeVBKSzVyPUG0MlA5PSEQvF2= M1;5[nNCVkeHUh?=
NCI-H2030 M17lZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF2LkG0OlUh|ryP MYLTRW5ITVJ?
HC-1 NHryRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfIfoFyUUN3ME2xOE4zODh5IN88US=> NWXP[HpoW0GQR1XS
QIMR-WIL NYDwXVN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHu4N|FKSzVyPUG0MlM1OTJizszN MoHDV2FPT0WU
Capan-2 M3iyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTVTWM2OD1zND6zO|E1KM7:TR?= NHXCeFlUSU6JRWK=
BALL-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjTNpRbUUN3ME2xOE41PjZ3IN88US=> MoPGV2FPT0WU
LS-1034 M4LKOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHqySFFKSzVyPUG0MlYyPTJizszN NXnWWY1PW0GQR1XS
U-118-MG Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;3eXJKSzVyPUG0MlY{OSEQvF2= MXnTRW5ITVJ?
NCI-H630 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF2Lk[1Olgh|ryP M{TON3NCVkeHUh?=
OVCAR-8 M2e3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF2LkeyNFEh|ryP Mn36V2FPT0WU
NCI-H2347 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:0PIpKSzVyPUG0MlgzOyEQvF2= MmT5V2FPT0WU
BT-549 NF7RWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEmye2RKSzVyPUG0MlgzQDRizszN MW\TRW5ITVJ?
LB831-BLC MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTyTWM2OD1zND64PVM1KM7:TR?= NUK2TY9oW0GQR1XS
NCI-H661 M1\kSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fld2lEPTB;MUSuPVU6KM7:TR?= MWnTRW5ITVJ?
MKN7 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDhSY1XUUN3ME2xOU4xODl|IN88US=> NV35TIpoW0GQR1XS
U-87-MG MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK4TWM2OD1zNT6wPFk4KM7:TR?= M{jUWXNCVkeHUh?=
OVCAR-4 NXLQeIR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\TZ45KSzVyPUG1MlE1OjRizszN NUDLUYU1W0GQR1XS
OE33 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHPTWM2OD1zNT6xO|EyKM7:TR?= MX\TRW5ITVJ?
EC-GI-10 M170Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnG2TWM2OD1zNT6yN|U4KM7:TR?= M{Lpe3NCVkeHUh?=
AM-38 MmX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXSxfnd3UUN3ME2xOU4zPzF5IN88US=> MYPTRW5ITVJ?
NCI-H1563 NUjnNI5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnYNlQyUUN3ME2xOU4{PDlizszN M2HzR3NCVkeHUh?=
SCC-4 MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrhTWM2OD1zNT60NVA{KM7:TR?= NXWxbWxYW0GQR1XS
Detroit562 M1fvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z2VmlEPTB;MUWuOFU1PyEQvF2= NHzoW2VUSU6JRWK=
PC-14 M3i4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX3S3RKSzVyPUG1MlQ5PjZizszN M1LKTnNCVkeHUh?=
ES3 M1TvNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnK3TWM2OD1zNT61N|Yh|ryP M2fEcnNCVkeHUh?=
OCI-AML2 NXq3THl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHL1WZRKSzVyPUG1Mlc3OTRizszN MWnTRW5ITVJ?
LU-134-A M3nhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfaTWM2OD1zNT65NFE5KM7:TR?= MXfTRW5ITVJ?
SAS M3rqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojRTWM2OD1zNT65N|c{KM7:TR?= MXPTRW5ITVJ?
TGBC11TKB NF\sXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTF3Lkm0NVQh|ryP MVPTRW5ITVJ?
HOP-62 M3vScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfDTWM2OD1zNT65OVk4KM7:TR?= NXP1So93W0GQR1XS
G-401 M1LKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHtTWM2OD1zNT65OlQ6KM7:TR?= NULHV3V6W0GQR1XS
NCI-H28 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;RUmlEPTB;MU[uNFg2PiEQvF2= MnKzV2FPT0WU
A204 M4\pVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XXXmlEPTB;MU[uNlAxPiEQvF2= M1POdnNCVkeHUh?=
NCI-H1299 NFvh[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[2dpV4UUN3ME2xOk4zOjlzIN88US=> NH\aOm9USU6JRWK=
VMRC-RCZ M{DSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\ydJNKSzVyPUG2MlI2QTJizszN NUfOdlY2W0GQR1XS
BxPC-3 M{HmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPpTWM2OD1zNj6yPFU3KM7:TR?= M4LoNHNCVkeHUh?=
NCI-H2228 Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF4LkWxOVgh|ryP M3TweHNCVkeHUh?=
NCI-H23 NWHSSIdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfwcZhjUUN3ME2xOk43ODd6IN88US=> NH\hNZFUSU6JRWK=
NKM-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfTR2RKSzVyPUG3MlAyQDlizszN M{PEVnNCVkeHUh?=
KYSE-70 NVXDPYx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml62TWM2OD1zNz6yPFkh|ryP M4rn[nNCVkeHUh?=
BB49-HNC NVHyRWxLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfXZWdKSzVyPUG3MlU3QDZizszN MVXTRW5ITVJ?
SCC-15 NV[wNoJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TENWlEPTB;MUeuPFQ4OyEQvF2= MWHTRW5ITVJ?
D-247MG M3rOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\0VWlEPTB;MUeuPVI1PyEQvF2= MkfnV2FPT0WU
BB30-HNC M3y5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDhTWM2OD1zOD6wN|E5KM7:TR?= NWjiN4l[W0GQR1XS
CAL-85-1 M2jXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHoUJpHUUN3ME2xPE4yQDB7IN88US=> NFfTdmFUSU6JRWK=
HT-3 NVe0bnVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF6LkO5O|ch|ryP MoP4V2FPT0WU
KYSE-410 MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LOSmlEPTB;MUiuOFU4PyEQvF2= NGn3TJFUSU6JRWK=
SW982 NV76R4V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn0TWM2OD1zOD61OlQ6KM7:TR?= M{PNVHNCVkeHUh?=
SW962 NEHnZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF6LkW3NFIh|ryP MULTRW5ITVJ?
Ramos-2G6-4C10 M3TSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrzWnBKSzVyPUG4MlU6OjdizszN NXHTfFZ2W0GQR1XS
OC-314 MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnrTWM2OD1zOD63N|g1KM7:TR?= NF;FcI9USU6JRWK=
LS-123 M1n6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTF6Lke5NFEh|ryP NFXOdWdUSU6JRWK=
D-502MG M3XWO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrjTWM2OD1zOD64NVM6KM7:TR?= MUXTRW5ITVJ?
RO82-W-1 M1PPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3TTWM2OD1zOD64Nlg5KM7:TR?= NUPoRWszW0GQR1XS
HuO9 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHETWM2OD1zOT6xN|c6KM7:TR?= M{i4fnNCVkeHUh?=
ETK-1 M13LRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPBWmREUUN3ME2xPU4yQDJ5IN88US=> M4jNSnNCVkeHUh?=
SNU-387 NWSwdHJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF7LkG4PFkh|ryP M3zNZ3NCVkeHUh?=
SW1573 MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq4TWM2OD1zOT6xPVY6KM7:TR?= NEezS|NUSU6JRWK=
NTERA-S-cl-D1 NWqxNYFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXLPWJKSzVyPUG5MlIxODdizszN NIK5NIhUSU6JRWK=
SF126 NFXBOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHKepFbUUN3ME2xPU4{PTB{IN88US=> MmLTV2FPT0WU
Calu-3 NVPBRolxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;FVmlEPTB;MUmuOFI{PyEQvF2= MUXTRW5ITVJ?
NCI-H1048 NEPZTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7YWZgzUUN3ME2yNE4{OjZ4IN88US=> MmTmV2FPT0WU
NCI-H226 M{fIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\zcFNKSzVyPUKwMlQ{QTlizszN NXzxTmhNW0GQR1XS
FTC-133 MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXESZNKSzVyPUKwMlQ4ODNizszN NGTrcWVUSU6JRWK=
SF539 NHzre3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjLcZhbUUN3ME2yNE42OTd{IN88US=> MWnTRW5ITVJ?
TE-6 M{Oyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLUe2ZTUUN3ME2yNE45ODZ5IN88US=> M37vXXNCVkeHUh?=
UMC-11 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITlV4VKSzVyPUKwMlkyPjRizszN M{ntSXNCVkeHUh?=
Becker NFTiS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnlfllKSzVyPUKxMlEyOThizszN M3\HXnNCVkeHUh?=
KP-4 Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLpTWM2OD1{MT6xNVk3KM7:TR?= NEjtVVRUSU6JRWK=
ChaGo-K-1 M4HNN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7tRWk6UUN3ME2yNU4{PjJ5IN88US=> M33tdHNCVkeHUh?=
CFPAC-1 NF3jR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vmXWlEPTB;MkGuN|g2QCEQvF2= MojxV2FPT0WU
A498 MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzJT5NQUUN3ME2yNU42OzF{IN88US=> NVqyRnVOW0GQR1XS
NCI-H1755 MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXpOW5yUUN3ME2yNU43PzRzIN88US=> NGP0NW9USU6JRWK=
TI-73 M1PjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K2VWlEPTB;MkKuN|I5KM7:TR?= NWTFSoZnW0GQR1XS
NCI-H441 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPSTWM2OD1{Mj61Olg6KM7:TR?= NITOem9USU6JRWK=
CaR-1 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETBfYhKSzVyPUKzMlAzOTNizszN NEPxS4NUSU6JRWK=
HCC1806 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljpTWM2OD1{Mz6wOVg{KM7:TR?= MWLTRW5ITVJ?
SNU-449 NI\xUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTZfJR{UUN3ME2yN{4{OjlizszN NED0OnlUSU6JRWK=
EKVX NEXlTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTVNXdKSzVyPUKzMlM6ODlizszN MofqV2FPT0WU
DMS-114 NVnsXGRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYH3eFVHUUN3ME2yN{42PzZ3IN88US=> Mm\UV2FPT0WU
A704 M2nufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJ|Lk[xNFMh|ryP NEOyXGxUSU6JRWK=
LC-2-ad MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXVTWM2OD1{Mz62NVQ4KM7:TR?= NEfvW3NUSU6JRWK=
VM-CUB-1 Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmraTWM2OD1{Mz63N|QyKM7:TR?= MU\TRW5ITVJ?
PC-3 MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vHR2lEPTB;MkSuNFUzPiEQvF2= M363PHNCVkeHUh?=
HEL M13OXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\IOGlEPTB;MkSuNFg3PSEQvF2= MnLnV2FPT0WU
ABC-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTMTWM2OD1{ND6yO|I6KM7:TR?= NFG4S3lUSU6JRWK=
COLO-680N MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PTT2lEPTB;MkSuOFc3PCEQvF2= MV7TRW5ITVJ?
MZ1-PC M{\Kcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHMZphnUUN3ME2yOE43QDdizszN MnSwV2FPT0WU
NCI-H69 M{GwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWCx[ZhrUUN3ME2yOE44OzV2IN88US=> NHzHd3dUSU6JRWK=
TE-1 MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrvfo1KSzVyPUK1MlA1QTlizszN NWm1dJpTW0GQR1XS
EW-3 Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorXTWM2OD1{NT6xNVMh|ryP M{TRfHNCVkeHUh?=
PANC-08-13 M{\0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfCcHB[UUN3ME2yOU45OTB|IN88US=> M2f1N3NCVkeHUh?=
NMC-G1 MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJ4LkCwPFgh|ryP MWPTRW5ITVJ?
BT-20 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3zcHFKSzVyPUK2MlQ2PDNizszN MmTsV2FPT0WU
TGBC24TKB M2HT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTJ4LkezN|Eh|ryP M{D3O3NCVkeHUh?=
TE-11 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X6WGlEPTB;Mk[uPVg6PSEQvF2= MUTTRW5ITVJ?
ESS-1 NFfP[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTJ5LkOyNVYh|ryP NYjMU|NKW0GQR1XS
JVM-3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ5Lk[0O|Uh|ryP MkXhV2FPT0WU
C3A MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj5[5p1UUN3ME2yO{45PDl4IN88US=> MlrGV2FPT0WU
MDA-MB-157 NGLzbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJ5Lki3OVMh|ryP NVTOW4w4W0GQR1XS
KLE MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v2bWlEPTB;MkiuNVA2QCEQvF2= NIjqR4lUSU6JRWK=
ES1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPDS2ZKSzVyPUK4MlE5OzhizszN NFn2Z5JUSU6JRWK=
CAL-120 M4rEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;kTWM2OD1{OD6zPVk6KM7:TR?= NYi5dpd4W0GQR1XS
NCI-N87 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn6zTWM2OD1{OD61NVA2KM7:TR?= Moi5V2FPT0WU
RPMI-8226 NYXROWFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rCb2lEPTB;MkmuNVg1OyEQvF2= Ml2wV2FPT0WU
COR-L88 M4\lWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrUOpE6UUN3ME2yPU4zPDF7IN88US=> NIj2eHBUSU6JRWK=
UACC-893 NGSzNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJ7LkOxN|ch|ryP NWDseZNxW0GQR1XS
C8166 NGjhOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJ7Lkm5PVYh|ryP NYX1cGM{W0GQR1XS
J82 NXTMRmYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHhVpp5UUN3ME2zNE45OTR5IN88US=> NGfjbFZUSU6JRWK=
PFSK-1 NF\UVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorTTWM2OD1|MT6wOlU6KM7:TR?= MX\TRW5ITVJ?
COLO-684 NUXoR|h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTNzLkSzO|Qh|ryP NGXncFdUSU6JRWK=
CAL-72 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXiTWM2OD1|MT61O|I6KM7:TR?= M{P3eXNCVkeHUh?=
SNB75 M3;icmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHYTWM2OD1|MT64PVch|ryP NU\nVo51W0GQR1XS
MDA-MB-415 NEjSfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTwTWM2OD1|MT65O|YzKM7:TR?= NFnJdYhUSU6JRWK=
SiHa NVnvUJpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjReI5KSzVyPUOyMlQ4OTFizszN MmGzV2FPT0WU
NCI-H1648 NXji[VFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\WSmlEPTB;M{KuPVM1PSEQvF2= MnPDV2FPT0WU
EFO-21 M4TESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTN|LkCwOUDPxE1? MVTTRW5ITVJ?
HCC38 NF;MWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTN|LkO4OFEh|ryP NW\ub4I6W0GQR1XS
IA-LM MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnGTWM2OD1|Mz63PFg6KM7:TR?= MUHTRW5ITVJ?
CTV-1 M2T3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon1TWM2OD1|Mz65O|g3KM7:TR?= NYLzWox[W0GQR1XS
NCI-H446 NYjOfGJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTN2LkK2PFkh|ryP NIL1[VJUSU6JRWK=
IST-SL1 M1PSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LuZWlEPTB;M{SuO|QxQCEQvF2= MYXTRW5ITVJ?
EW-22 NYjE[oJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTVTWM2OD1|ND63O|U6KM7:TR?= M2fZ[XNCVkeHUh?=
JEG-3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe0eZFKSzVyPUO2MlE4PjZizszN NHHtb2ZUSU6JRWK=
LU-65 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrWXlBKSzVyPUO2MlI6QDVizszN NYLvOGlVW0GQR1XS
NCI-H596 M4f0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLnTWM2OD1|Nj65OVkyKM7:TR?= NYrBUop3W0GQR1XS
KNS-81-FD MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEixUIxKSzVyPUO3MlE1PSEQvF2= M1y1XHNCVkeHUh?=
NCI-H1793 M360S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nmXmlEPTB;M{euO|A5PiEQvF2= NYTxVXpIW0GQR1XS
NCI-H460 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvqe2x[UUN3ME2zPE4xQDd|IN88US=> NGHmeYRUSU6JRWK=
MPP-89 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjxVpVmUUN3ME2zPU42QDh4IN88US=> NHm3d2tUSU6JRWK=
D-542MG MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTN7Lki0N|Yh|ryP M{X1WHNCVkeHUh?=
JAR NFPmVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfGfml6UUN3ME20NE41PzB3IN88US=> MX3TRW5ITVJ?
NCI-H209 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTRyLk[3O{DPxE1? NGPBOmhUSU6JRWK=
G-402 M1fWXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPVN3VKSzVyPUSxMlM6QTNizszN M2DjW3NCVkeHUh?=
IST-MES1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTR{LkG5N|Uh|ryP M4nCWnNCVkeHUh?=
Daoy MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjhUZZKSzVyPUSyMlU1PzFizszN MnmzV2FPT0WU
EW-11 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzJZpJ5UUN3ME20N{4yOjFzIN88US=> NV;XSIZbW0GQR1XS
Saos-2 M1\0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTR|LkG1N|ch|ryP MXfTRW5ITVJ?
no-10 NXLHVHU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH5UJFKSzVyPUSzMlE4ODJizszN M4\o[XNCVkeHUh?=
HCC1395 MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTR|LkS2OFQh|ryP NWK3Onh3W0GQR1XS
HCE-4 NHT0OodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfk[3hKSzVyPUSzMlc3PjRizszN MXTTRW5ITVJ?
EW-1 M3SyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTR|LkiwOFkh|ryP NGTUZoVUSU6JRWK=
OCUB-M M1OzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17xZmlEPTB;NESuN|Y{QCEQvF2= M4ftVHNCVkeHUh?=
IGR-1 NV\xUoNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHlTWM2OD12ND60NVE2KM7:TR?= NHzOUW9USU6JRWK=
NCI-H1838 NXLVeJp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\l[ZFKUUN3ME20OE41OzR7IN88US=> NYPOPWtOW0GQR1XS
NCI-H2405 NHfZUWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTR2LkWzOEDPxE1? NUPONJh{W0GQR1XS
GB-1 NF;KSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDJTWM2OD12ND63OFY{KM7:TR?= M174enNCVkeHUh?=
MG-63 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzMTWM2OD12Nj6wOlk3KM7:TR?= MU\TRW5ITVJ?
KP-N-YN NVXFXHJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfBdXBKSzVyPUS2MlQ3PzlizszN MoXQV2FPT0WU
no-11 NH;tR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHGU25KSzVyPUS3MlAzPDRizszN NYTOdVdnW0GQR1XS
SW948 Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP0dHhKSzVyPUS3MlM{PzdizszN NH;qUoJUSU6JRWK=
CAMA-1 NEDtR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPwTWM2OD12Nz6zOFM5KM7:TR?= MYnTRW5ITVJ?
HCC1187 NIX4Xo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfrT2FOUUN3ME20O{42OSEQvF2= NXT3bYp5W0GQR1XS
D-392MG M3TWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TJUWlEPTB;NEeuOlUyPiEQvF2= M4GwVnNCVkeHUh?=
647-V MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTR7LkO0NVQh|ryP MUXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]

Protocol

Kinase Assay:

[2]

+ Expand

MEK1 Assay:

MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research:

[1]

+ Expand
  • Cell lines: Colon 26 carcinoma cells
  • Concentrations: 0.1-10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: PTC cells in athymic mice
  • Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water
  • Dosages: 150 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 10 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID